TORONTO, April 17, 2018 /CNW/ - Eric Adams, President & CEO, InMed Pharmaceuticals Inc. (IN), joined Shaun McIver, Chief Client Officer, TMX Group, to open the market. InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed Pharmaceuticals Inc. commenced trading on Toronto Stock Exchange on March 26, 2018.
SOURCE TMX Group Limited